carbonic anhydrase i

Tioxolone is a metalloenzyme carbonic anhydrase I inhibitor.

hCAI/II-IN-6 is a selective and orally active inhibitor of human carbonic anhydrase (CA). hCAI/II-IN-6 inhibited hCA I, hCA II, hCA VII, and hCA XII with Ki values of 220, 4.9, 6.5, and ＞50,000 nM. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy. hCAI/II-IN-6 showed anticonvulsant activity in vivo. hCAI/II-IN-6 can be used to study epilepsy.

Carbonic anhydrase inhibitor30 (compound 17) is an inhibitor of carbonic anhydrase with Ki values of 2.13 μM for hCA I and 0.161 μM for hCA II[1].

Carbonic anhydrase inhibitor32 (compound 5B) is an orally active, selective inhibitor of hCA (carbonic anhydrase) II/VII, with Ki values of 6.3 nM for hCA II, 10.1 nM for hCA VII, and 681 nM for hCA I. It shows potential for neuroprotection and anticonvulsant effects by reducing mTOR activation and increasing hippocampal KCC2 levels.

Carbonic anhydrase inhibitor 4 is a photoprobe that inhibits the activity of carbonic anhydrase. It specifically targets human carbonic anhydrases, including hCA I-XIV, with K i values ranging from 640-1166 nM [1].

Carbonic anhydrase inhibitor 14 (Compound 8b) is a potent CA inhibitor, exhibiting K i values of 1203, 99.7, 9.4, and 27.7 nM against hCA I, hCA II, hCA IX, and hCA XII, respectively. Additionally, it effectively inhibits CDK2 with an IC 50 of 20.3 μM and demonstrates significant antitumor activity [1].

Carbonic anhydrase inhibitor 8 (compound R-13) is a potent human carbonic anhydrase (hCA) with K i values of 60.7 nM, 320.7 nM, and 2298 nM for hCA I, hCA II, and hCA IV, respectively.

Human carbonic anhydrase II-IN-1 (Compound S-13) is a potent human carbonic anhydrase II (hCA II) inhibitor. Human carbonic anhydrase II-IN-1 shows Kis of 4.4 nM, 9.2 nM, 480.2 nM and 14.7 nM for hCA II, I, IV and IX, respectively. Human carbonic anhydrase II-IN-1 can be used for glaucoma research.

Human carbonic anhydrase II-IN-24 (Compound R-13) is a potent human carbonic anhydrase (hCA) inhibitor. Human carbonic anhydrase II-IN-24 shows K i s of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively.

Carbonic anhydrase inhibitor 7 is a potent inhibitor of human carbonic anhydrase (hCA), acting on hCA IX (Ki: 6.5 nM), hCA II (Ki: 7.1 nM), hCA XII (Ki: 72.1 nM) and hCA I (Ki: 255.8 nM).

Carbonic anhydrase inhibitor 6 is a potent human carbonic anhydrase (hCA) inhibitor that inhibits hCA IX, hCA II, hCA XII, and hCA I. It is used in the study of diseases caused by abnormalities in carbonic anhydrase.

Carbonic Anhydrase Inhibitor 12 is a potent inhibitor of CA II, with additional inhibitory activity against CA I, exhibiting K_i values of 1.72 nM for CA II and 271 nM for CA I. Moreover, it demonstrates significant anticancer activity across various cancer cell lines [1].

Carbonic anhydrase inhibitor 16 (compound 1) is a potent and selective carbonic anhydrase (CA I/CA II) inhibitor, with potential antiviral activity, used in viral infection research.

Compound 6T, designated as Carbonic anhydrase inhibitor26, acts as an inhibitor of Carbonic Anhydrase II (Carbonic AnhydraseII), exhibiting an IC50 value of 9.10 ± 0.26 μM.

Carbonic anhydrase inhibitor28 (Compound 11) serves as an inhibitor for the Pseudomonas aeruginosa carbonic anhydrase. It exhibits antibacterial activity, with minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values of 0.5 and 1 μg mL, respectively, against P. aeruginosa. Carbonic anhydrase inhibitor28 is utilized in research focused on anti-infection applications.

Carbonic anhydrase inhibitor29 (Compound 5d) is an inhibitor targeting carbonic anhydrase IX and XII, with an inhibition constant (Ki) of 26.6 nM for carbonic anhydrase IX and a Ki of 10.9 nM for carbonic anhydrase XII. Carbonic anhydrase inhibitor29 can be used in cancer research.

Carbonic anhydrase inhibitor31 is an mtCA2 inhibitor (Ki: 5.2 nM) that can be used in antituberculosis research.

Carbonic anhydrase inhibitor33 (11D) is a dual inhibitor that targets both CA (carbonic anhydrase) IX/XII and CDK6. It exhibits Ki values of 19.7 nM for hCA IX and 26.1 nM for hCA XII. Additionally, Carbonic anhydrase inhibitor33 (11D) can induce G1 phase cell cycle arrest and apoptosis, making it relevant for research in non-small cell lung cancer (NSCLC).

Carbonic anhydrase inhibitor 3 (compound 11g) is a carbonic anhydrase II inhibitor that reduces intraocular pressure in glaucomatous rabbits [1].

Carbonic anhydrase inhibitor 10 can be used in the research of cancer that shows anti-proliferative activity against MCF-7 cancer cell line with an IC50 of 11.9 μM. Carbonic anhydrase inhibitor 10 is a potent inhibitor of h CA IX with a Ki value of 6.2 nM [1].

Compound 7c, identified as carbonic anhydrase inhibitor 1, effectively inhibits carbonic anhydrase II. This inhibitor, also known as carbonic anhydrase inhibitor 3, lowers intraocular pressure in glaucomatous rabbits [1].

Carbonic anhydrase inhibitor 13 (compound 7) is a potent inhibitor of carbonic anhydrase (CA).

Carbonic anhydrase inhibitor 5 is a potent and selective inhibitor of human carbonic anhydrase (hCA), targeting hCA II (IC50: 42.9 nM), hCA IX (IC50: 47.6 nM), and hCA XII (IC50: 6.7 nM).

Carbonic anhydrase inhibitor 11 (compound VI) is a potent, selective inhibitor of carbonic anhydrase, targeting CA II (Ki: 40 nM), CA IX (Ki: 39 nM), and CA XII (Ki: 900 nM).